PepGen (PEPG) Earnings Date & Reports

Key Takeaways

• PepGen reported a net loss of $19.4 million, or $0.28 per share, for the third quarter ended September 30, 2026.
• The per-share loss came in slightly wider than the consensus estimate of a $0.27 loss.
• Alongside results, PepGen disclosed positive topline data from the 10 mg/kg cohort of its FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
• Cash, cash equivalents, and marketable securities totaled $104.8 million, which management expects to fund operations into 2028.
• Research and development (R&D) expenses rose to $14.5 million from $13.4 million a year earlier, while general and administrative (G&A) expenses increased to $5.9 million.
• The U.S. FDA selected PGN-EDODM1 for its CMC Development and Readiness Pilot program, aimed at de-risking manufacturing development.
• For additional context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• To discover data-driven trade ideas across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

As a clinical-stage biotechnology company, PepGen generates no product revenue, so its quarterly earnings release functions less as a measure of sales and more as a checkpoint on cash discipline, spending trajectory, and clinical execution. Investors focus primarily on the progress of PGN-EDODM1, the company's lead candidate for myotonic dystrophy type 1 (DM1), a rare, progressive neuromuscular disease with no approved disease-modifying therapies. This quarter carried extra weight because results arrived alongside the long-awaited topline readout from the 10 mg/kg cohort of the FREEDOM2-DM1 trial, a milestone management had flagged earlier in the year. Combined, the financials and the data update give the market a clearer view of both PepGen's balance-sheet runway and the clinical signal supporting its lead program.

Reported Results

For the third quarter of 2026, PepGen posted a net loss of $19.4 million, or $0.28 basic and diluted net loss per share, compared with a net loss of $18.0 million, or $0.52 per share, in the same period a year earlier. The result narrowly missed the consensus estimate of a $0.27 per-share loss. As expected for a pre-revenue company, PepGen recorded no product sales.

R&D expenses were $14.5 million, up from $13.4 million a year ago, reflecting advancing clinical activity. G&A expenses rose to $5.9 million from $5.2 million. The company ended the quarter with $104.8 million in cash, cash equivalents, and marketable securities and approximately 69.3 million shares outstanding. Management said the current cash position is expected to fund operations into 2028, an extension from the prior "into 2H 2027" guidance.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For those following clinical-stage names like PepGen, the screener can help surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening. Explore the AI Screener to build your own market scans.

Market Reaction and Investor Sentiment

Sentiment around PepGen's third-quarter report was shaped less by the modest earnings miss than by the simultaneous clinical data release. Because PepGen is pre-revenue, a one-cent difference in the per-share loss typically matters less to investors than the direction of the lead program. The positive topline results from the 10 mg/kg cohort of FREEDOM2-DM1 gave investors a tangible data point on PGN-EDODM1's safety and activity at a higher dose, while the extended cash runway into 2028 reduced near-term financing overhang. Still, the trial remains subject to a partial clinical hold in the United States, which continues to be a key risk factor that investors are monitoring alongside the progression toward higher-dose cohorts and future regulatory engagement.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central catalyst for PepGen remains the FREEDOM2-DM1 program. Results from the highest-dose 12.5 mg/kg cohort are expected in the first half of 2027, and the company has said it plans to engage with regulators in an end-of-Phase 2 meeting to discuss a potential registrational program pending results from the 10 and 12.5 mg/kg cohorts.

Regulatory progress will also be important. The partial clinical hold imposed by the U.S. FDA remains in place, and how quickly PepGen resolves the agency's preclinical questions could influence U.S. trial timelines even though enrollment outside the U.S. has continued.

On the financial side, investors will watch whether the company's stated runway into 2028 holds as trial activity expands, and whether R&D spending continues to climb as later-stage cohorts and open-label extension work advance. The FDA's selection of PGN-EDODM1 for the CMC Development and Readiness Pilot program may also shape manufacturing-readiness planning ahead of any Phase 3 program. Taken together, data readouts, regulatory milestones, and cash management will likely drive the stock's narrative over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations